Aluminum chelation therapy

Hematological Effects. Hematological effects have not been observed in humans or animals with normal renal function. However, microcytic, hypochromatic anemia has been observed in individuals with impaired renal function. The anemia is unresponsive to iron therapy. The severity of the anemia correlates with plasma and erythrocyte aluminum levels and can be reversed by terminating aluminum exposure and chelation therapy with DFO. 

Heavy Metal Intoxication Chelators), also binds aluminum and is being used as therapy for this disorder. 

Extracorporeal blood purification therapies do not efficiently remove heavy metals or their salts. Chelating agents can be combined with dialysis modalities and hemoperfusion to improve the clearance of aluminum, iron, and other metals. 

---